Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in haemophilia patients with inhibitors and has also been used successfully in non-haemophilia patients with acquired antibodies against FVIII (acquired haemophilia). Based on dose-fi... ...
